Subscribe to stay informed!
Recro Pharma’s stock took a major hit after the FDA rejected a new drug application for the Malvern company’s non-opioid pain medication…
Malvern’s Recro Pharma is already preparing for the potential commercial launch of its highly anticipated new drug with a $35.9 million public stock…
Before we send you to this site, please subscribe to our daily newsletter.